Bunge Limited
BG
$110.86
-0.50%
Bunge Global SA is a leading global agribusiness and food company, operating in the Agricultural Farm Products sector within Consumer Defensive. It functions as a critical link in the agricultural supply chain, connecting farmers to consumers by processing and merchandising oilseeds and grains into essential food, feed, and fuel products, with its Soybean Processing and Refining segment being the primary revenue driver. As a major player in a consolidated global industry, Bunge's competitive identity is that of a low-cost, integrated processor and merchandiser with a vast global logistics network. The current investor narrative is focused on the company's ambitious long-term strategic goals, including a target for mid-cycle EPS of $15 by 2030, which signals management's confidence in structural margin improvements and shareholder returns, even as the stock contends with near-term volatility from fluctuating agricultural commodity prices and processing margins.…
BG
Bunge Limited
$110.86
Related headlines
Investment Opinion: Should I buy BG Today?
Rating: Hold. The core thesis is that BG presents a compelling long-term value proposition clouded by severe near-term cyclical headwinds, making it appropriate for patient, risk-tolerant investors but too uncertain for a clear Buy rating at this juncture.
The Hold rating is supported by four specific data points. First, valuation is deeply discounted on a forward basis (P/E of 10.34x) and on assets (P/B of 0.92). Second, analyst sentiment remains bullish among major firms, suggesting institutional confidence in a recovery. Third, revenue growth remains robust at 75.5% YoY, demonstrating operational scale. Fourth, the company maintains adequate liquidity with a current ratio of 1.61 and positive TTM free cash flow. However, these positives are counterbalanced by the drastic margin collapse evident in the Q4 net margin of 0.40%.
The two biggest risks invalidating a potential upgrade are: 1) Further gross margin compression below 4%, signaling a structural rather than cyclical problem, and 2) A breakdown below the $100 psychological support level, confirming the technical downtrend. This Hold would upgrade to a Buy if quarterly gross margins stabilize and rebound above 5.5%, or if the forward P/E compresses further toward 8x on sustained earnings weakness. It would downgrade to a Sell if net income turns negative or debt levels increase meaningfully from the current D/E of 0.997. Relative to its history and low-margin peers, the stock is fairly valued to slightly undervalued, but the discount is justified by the current downcycle.
Sign up to view all
BG 12-Month Price Forecast
The outlook for BG is a battle between compelling valuation and deteriorating fundamentals. The low forward P/E and asset-based discounts are powerful attractors, but they are fully warranted by the severe profit margin collapse witnessed in the latest quarter. The base case of a slow, grinding recovery is most probable, but the wide target range reflects the stock's high sensitivity to commodity spreads. The stance is neutral because the risk of further downside from failed margin recovery is balanced by the asymmetric upside if management's long-term targets gain traction. We would upgrade to bullish on concrete evidence of margin stabilization (e.g., two consecutive quarters of gross margin >5%), and downgrade to bearish on a breakdown below $100 support coupled with another quarter of sub-1% net margins.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Bunge Limited's 12-month outlook, with a consensus price target around $144.12 and implied upside of +30.0% versus the current price.
Average Target
$144.12
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$89 - $144
Analyst target range
Analyst coverage for Bunge Global is limited, with only 3 analysts providing estimates, which is relatively sparse for a company of its size and suggests it may be under-followed compared to other large-cap stocks. The consensus sentiment, inferred from recent institutional ratings, is bullish, with firms like JP Morgan, Morgan Stanley, Barclays, and UBS maintaining 'Overweight' or 'Buy' ratings as recently as March 2026. The average revenue estimate for the period is $96.03 billion, with a high estimate of $97.25 billion and a low of $94.81 billion, indicating a tight range and consensus on the top-line outlook. The average EPS estimate is $11.59, with a range from $11.16 to $12.00. The implied upside or downside from the current price cannot be calculated precisely without a specific consensus price target, but the maintained bullish ratings by major firms in early 2026, even as the stock price has fallen, suggest analysts see value at current levels. The recent news of the company's 2030 EPS target of $15 likely forms the basis for the high-end analyst scenarios, while the low end may reflect concerns about near-term margin headwinds and commodity price volatility. The pattern of reiterated 'Overweight' and 'Buy' ratings in Q1 2026, without downgrades, signals that the institutional analyst community is looking through the current cyclical weakness toward the long-term strategic goals.
Bulls vs Bears: BG Investment Factors
The bull and bear cases for BG are in sharp tension, with the bears currently holding stronger near-term evidence due to severe margin compression and technical breakdown. The bulls' thesis rests on deep value metrics and a long-term strategic vision, but it requires a belief in a cyclical earnings recovery that recent quarterly data has yet to confirm. The single most important investment debate is whether the current margin collapse is a temporary trough in a volatile commodity cycle (bull view) or a sign of structural degradation in processing spreads (bear view). The resolution of this margin trajectory over the next 2-3 quarters will determine if the stock's low forward P/E of 10.34x is a trap or a springboard.
Bullish
- Deep Value on Forward Earnings: The forward P/E of 10.34x is exceptionally low, pricing in a significant earnings recovery from the depressed Q4 2025 net margin of 0.40%. This valuation is below the trailing P/E of 17.95x and suggests the market is discounting a cyclical rebound, offering a compelling entry point if management's $15 EPS 2030 target is credible.
- Strong Analyst Conviction Amid Weakness: Major institutions like JP Morgan and Morgan Stanley maintained 'Overweight' or 'Buy' ratings in March 2026 despite the stock's sharp correction. This indicates professional analysts see the recent 17.8% decline from the 52-week high as a buying opportunity, looking through near-term margin volatility toward long-term strategic goals.
- Robust Revenue Growth Trajectory: Q4 2025 revenue grew 75.5% year-over-year to $23.76 billion, and sequential quarterly revenue more than doubled from Q1 to Q4 2025. This demonstrates strong top-line momentum and scale, even if driven by volatile commodity prices, affirming the company's critical role in the global agribusiness supply chain.
- Attractive Asset-Based Valuation: The stock trades at a Price-to-Book ratio of 0.92 and a Price-to-Sales ratio of 0.21x, both below 1.0. This indicates the market values BG below its reported asset base and revenue stream, a classic value signal for a capital-intensive business with a vast global logistics network.
Bearish
- Severe Profit Margin Compression: Q4 2025 net margin collapsed to 0.40% from 4.45% a year ago, and gross margin fell to 4.25% from 7.98%. This drastic compression in core Soybean Processing spreads is the central operational challenge, directly causing net income to plummet to $95M from $602M YoY and raising doubts about near-term earnings power.
- Sharp Technical Breakdown & Weak Momentum: The stock price of $112.58 sits near the bottom 17.8% of its 52-week range, having fallen 7.92% in the past month while the S&P 500 gained 0.74%. This severe relative weakness (-8.66% RSI) suggests a loss of bullish momentum and potential for a deeper correction towards the $71.60 low, indicating strong selling pressure.
- High Cyclicality and Earnings Volatility: The extreme swing from a trailing P/E of 54.28x in Q2 2024 to 17.95x today underscores the stock's high earnings volatility. ROE is a modest 5.15%, and the business model is inherently tied to unpredictable agricultural commodity prices and processing spreads, making consistent profitability difficult.
- Limited Analyst Coverage & Visibility: With only 3 analysts providing estimates, BG is relatively under-followed for a $14.7B market cap company. Sparse coverage can lead to lower liquidity, greater price gaps, and reduced market efficiency, increasing the risk of mispricing and heightened volatility on news flow.
BG Technical Analysis
The stock is in a sustained long-term uptrend but has recently entered a significant correction. Over the past year, the price has appreciated 31.60%, indicating a strong bullish trend. However, with a current price of $112.58, the stock is trading at approximately 17.8% of its 52-week range ($71.60 to $134.87), having retreated sharply from its highs and now sitting much closer to the lower bound, suggesting a loss of momentum and potential oversold conditions. Recent momentum has turned sharply negative, diverging from the longer-term uptrend. The stock has declined 7.92% over the past month and 4.71% over the past three months, which contrasts with the S&P 500's gains of 0.74% and 15.14% over the same periods, respectively, indicating significant relative weakness and a potential trend reversal or consolidation phase. Key technical support is at the 52-week low of $71.60, while resistance is at the recent high of $134.87. A breakdown below the recent low of $112.58 could signal a deeper correction towards the $100 psychological level, while a recovery above $130 would be needed to re-establish the uptrend. The stock's beta of 0.617 indicates it is approximately 38% less volatile than the broader market, which historically provided some downside protection but has not prevented the recent sharp sell-off.
Beta
0.62
0.62x market volatility
Max Drawdown
-15.6%
Largest decline past year
52-Week Range
$72-$135
Price range past year
Annual Return
+31.7%
Cumulative gain past year
| Period | BG Return | S&P 500 |
|---|---|---|
| 1m | -8.2% | -1.6% |
| 3m | -11.6% | +11.7% |
| 6m | +25.0% | +6.3% |
| 1y | +31.7% | +22.2% |
| ytd | +19.7% | +7.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BG Fundamental Analysis
Revenue growth has been robust but volatile, reflecting the cyclical nature of agricultural commodities. The most recent quarterly revenue (Q4 2025) was $23.76 billion, representing a significant 75.5% year-over-year increase. However, examining the sequential quarterly trend from Q1 2025 ($11.64B) to Q4 2025 ($23.76B) shows revenue more than doubling, though this is heavily influenced by seasonality and commodity price movements; the core driver remains the Soybean Processing segment, which is sensitive to crush margins and global demand. Profitability has compressed significantly from prior peak levels. Net income for Q4 2025 was $95 million, a sharp decline from $602 million in Q4 2024, with the net margin contracting to 0.40% from 4.45% a year ago. Gross margin for the latest quarter was 4.25%, down from 7.98% in Q4 2024, indicating severe pressure on processing spreads. This margin compression is the central challenge, as the company navigates a normalization from historically high earnings. The balance sheet and cash flow position remains manageable but shows the impact of working capital cycles. The debt-to-equity ratio is 0.997, indicating a balanced capital structure with nearly equal debt and equity. Free cash flow on a TTM basis is $296 million, providing some internal funding capacity. The current ratio of 1.61 suggests adequate short-term liquidity. Return on Equity (ROE) stands at 5.15%, which is modest and reflects the current period of compressed profitability.
Quarterly Revenue
$23.8B
2025-12
Revenue YoY Growth
+0.75%
YoY Comparison
Gross Margin
+0.04%
Latest Quarter
Free Cash Flow
$296000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BG Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 17.95x, while the forward PE is significantly lower at 10.34x, based on estimated EPS of $11.59. This substantial gap implies the market expects a strong earnings recovery in the coming year, pricing in the anticipated rebound from current depressed profitability levels. Compared to industry averages, Bunge's valuation appears mixed. Its trailing PE of 17.95x is below the typical market average for profitable firms, but more relevant is its Price-to-Sales (PS) ratio of 0.21x and EV/Sales of 0.49x, which are low and characteristic of low-margin, high-volume commodity businesses. The stock trades at a Price-to-Book (PB) ratio of 0.92, indicating the market values the company slightly below its reported book value, which could be interpreted as a discount or a reflection of asset-heavy, cyclical industry norms. Historically, the stock's own valuation has compressed from higher levels. The current trailing PE of 17.95x is below the historical high observed in recent quarters (e.g., 45.71x in Q4 2025 and 54.28x in Q2 2024) and is more in line with its longer-term average, suggesting the market has already priced in the earnings decline. Trading near the lower end of its historical PE band could indicate a value opportunity if the company's $15 EPS 2030 target is credible, but it also reflects the current downcycle in agribusiness profits.
PE
18.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 3x~54x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are pronounced, centered on collapsing profitability within a leveraged structure. The Q4 2025 net margin of 0.40% and gross margin of 4.25% represent severe compression from prior levels, directly threatening the company's ability to service its debt, which stands at a Debt-to-Equity of 0.997. Free Cash Flow (TTM) of $296M provides a buffer, but the business model is capital-intensive and working capital-heavy, leaving cash flow vulnerable to commodity price swings. The core risk is that depressed Soybean Processing margins persist longer than anticipated, preventing the earnings rebound priced into the forward P/E of 10.34x.
Market & Competitive Risks stem from its cyclical nature and valuation. While the stock's beta of 0.617 suggests lower market volatility, it has shown high idiosyncratic risk, falling 7.92% in a month when the market rose. Trading at a P/B of 0.92 may seem like a discount, but it is characteristic of low-margin, asset-heavy commodity processors and could compress further if ROE remains near 5.15%. Competitive risks are inherent in a consolidated global industry where pricing power is limited by commodity markets. The recent news highlighting the ambitious 2030 EPS target also sets a high bar, creating execution risk and potential for disappointment if near-term headwinds persist.
Worst-Case Scenario involves a prolonged downturn in global agricultural processing margins coupled with a broader risk-off market environment. In this scenario, earnings fail to recover, the $15 EPS 2030 target is abandoned, and the stock re-rates to reflect permanently lower profitability. The chain of events could include consecutive quarterly misses, analyst downgrades from the current bullish stance, and a breach of key technical support. The realistic downside would be a retest of the 52-week low of $71.60, representing a loss of approximately -36% from the current price of $112.58. Historical volatility and the commodity-sensitive nature of the business make this a plausible, though not base-case, adverse outcome.
FAQ
The key risks, ranked by severity, are: 1) Profit Margin Risk: The collapse in Q4 gross margin to 4.25% may persist or worsen, crippling earnings. 2) Commodity Price & Cycle Risk: The business is inherently tied to volatile agricultural commodity prices and processing spreads outside its control. 3) Financial Leverage Risk: A Debt-to-Equity ratio of 0.997 amplifies pain during downturns, as seen with $216M in Q4 interest expense. 4) Execution & Target Risk: Management's ambitious $15 EPS 2030 target may prove unrealistic, leading to investor disappointment and multiple compression. The stock's recent 17.8% decline from its high demonstrates the materiality of these risks.
The 12-month forecast presents three scenarios. The Base Case (50% probability) sees a slow recovery with a target range of $115-$125, assuming BG meets the $11.59 EPS consensus and the forward P/E holds near 10-11x. The Bull Case (30% probability) projects a return to the 52-week high of $134.87 and beyond, driven by a sharp margin recovery and P/E expansion. The Bear Case (20% probability) warns of a drop toward the 52-week low of $71.60 if margins remain depressed. The base case is most likely, but the wide dispersion highlights the stock's high sensitivity to unpredictable commodity processing margins.
BG appears undervalued on a forward earnings and asset basis, but this discount is justified by current fundamentals. The forward P/E of 10.34x is low and implies a strong earnings rebound from the depressed $11.59 EPS estimate. The stock trades below its book value (P/B of 0.92) and at a deep discount to sales (P/S of 0.21x). However, compared to its own history, the trailing P/E of 17.95x has compressed from over 54x, reflecting the market's accurate pricing of the earnings decline. The valuation is fair-to-cheap, but it is a value trap if margins do not recover as anticipated.
BG is a speculative buy for value-oriented, risk-tolerant investors with a long-term horizon. The forward P/E of 10.34x and P/B ratio of 0.92 suggest significant undervaluation if earnings recover. However, it is not a good buy for conservative investors, as severe near-term margin compression (Q4 net margin 0.40%) and a 7.92% monthly price decline indicate high uncertainty and volatility. The decision hinges on one's belief in a cyclical rebound; it could be a good buy for those convinced the agribusiness cycle is near a trough, but a poor choice for those seeking stability or near-term capital appreciation.
BG is suitable only for long-term investment with a minimum horizon of 3-5 years. Its low beta of 0.617 and essential business model support a long-term hold, but extreme quarterly earnings volatility and cyclicality make it a poor short-term trading vehicle. The investment thesis is based on a full commodity cycle recovery and the execution of a multi-year strategic plan targeting 2030. Short-term traders would be exposed to unpredictable swings from crop reports and margin data. Therefore, it is best suited for a patient, long-term portfolio allocation within a diversified value or commodities sleeve.